The unexpected appearance of the monkeypox virus and the extensive geographic dispersal of cases have prompted researchers to concentrate on potential therapeutic approaches. In addition to its vaccine build techniques, there should be some multiple integrated antiviral active compounds because of the MPV (monkeypox virus) outbreak in 2022. This study offers a computational engineering-based de novo drug discovery mediated by random antiviral active compounds that were screened against the virulent protein MPXVgp169, as one of the key players directing the pathogenesis of the virus. The screening of these candidates was supported by the use of 72 antiviral active compounds. The top candidate with the lowest binding affinity was selected for the engineering of chains or atoms. Literature assisted to identify toxic chains or atoms that were impeding the stability and effectiveness of antiviral compounds to modify them for enhanced efficacy. With a binding affinity of −9.4 Kcal/mol after chain, the lipophilicity of 0.41, the water solubility of 2.51 as soluble, and synthetic accessibility of 6.6, chain-engineered dolutegravir was one of the best active compounds, as proved by the computational engineering analysis. This study will revolutionize the era of drug engineering as a potential therapeutic strategy for monkeypox infection.
Polycystic Ovary Syndrome (PCOS) is a prevalent and complex endocrine disorder affecting reproductive-aged women, characterized by hormonal imbalances, ovarian dysfunction, and metabolic disturbances. This study investigates the biological properties of curcumin-conjugated zinc oxide nanoparticles (Cur-ZnO NPs) synthesized via a green method using Livistona Chinensis leaf extract. Plant extract metabolites acted as natural capping and reducing agents, facilitating the formation of ZnO nanoparticles. The synthesized Cur-ZnO NPs were characterized using UV–vis spectroscopy, Fourier Transform Infrared (FTIR) spectroscopy, Scanning Electron Microscopy (SEM), and Energy Dispersive X-ray (EDX), revealing a spherical morphology with an average size of 30 nm and the presence of zinc oxide groups. In vitro assays demonstrated the biological activities of Cur-ZnO NPs, including 96.17 % antioxidant, 94.45 % anti-inflammatory, 92.72 % α -amylase inhibitory activity, 7 % anti-hemolytic, and significant antimicrobial properties. Computational analyses, including transcriptomic evaluation and molecular docking studies, revealed molecular interactions between the nanoparticles and PCOS associated genes such as MRPS12, RPS18, and RPS5 indicating potential biological relevance. Toxicity predictions indicated low predicted genetic toxicity and carcinogenicity, although these findings are preliminary and require experimental validation. Collectively, this study provides preliminary in vitro and in-silico insights into the biological properties of Green-synthesised Cur-ZnO NPs. Further in vivo studies are required to evaluate their safety, efficacy, and potential biomedical applications.